



IFW

PATENT  
Customer No. 22,852  
Attorney Docket No. 9914.0006-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
Antoine MAYR et al. ) Group Art Unit: 1648  
Application No.: 10/587,082 ) Examiner: Blumel, Benjamin P.  
Filed: July 21, 2006 ) Confirmation No.: 6952  
For: MONOPARAMUNITY INDUCERS BASED  
ON ATTENUATED RABBIT MYXOMA VIRUSES (As amended)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

In an Office Action dated September 24, 2007, the Examiner required restriction of the pending claims to one of the following groups for examination:

- I. Claims 46-55, drawn to a method of culturing a myxomavirus.
- II. Claims 56-57 and 66-69, drawn to a myxomavirus pharmaceutical composition.
- III. Claims 58-65, drawn to a method of vaccinating a host.

Applicant elects Group I, claims 46-55.

The Examiner further required that, if Group I is elected, a specific species of either Vero monkey cells or AVIVER cell culture, as recited in claims 48 and 52, must also be elected.

Applicant elects AVIVER cell culture, as recited in claims 52-55.

The Examiner further required that, if Group I is elected, a specific species of number of passages, as recited in claims 49-51 and 53-55, must also be elected.

Applicant elects at least 50 passages, as recited in claim 55.

Claims 46, 47, and 52-55 read on the elected species of AVIVER cell culture and at least 50 passages.

Applicant disagrees with the Examiner's allegation that Applicant's claims do "not define a contribution over the prior art." (Office Action at 2.) Applicant will await an explanation of this contention before fully responding to it.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Respectfully submitted,

Dated: October 24, 2007

By: \_\_\_\_\_

  
Salvatore J. Arrigo  
Registration No. 48,063  
Telephone: 202-408-4160  
Facsimile: 202-408-4400  
E-mail: arrigos@finnegan.com